Arthritis Drug Shows Hair Regrowth for Severe Alopecia in Clinical Trials

Upadacitinib, an arthritis medication, achieved measurable hair regrowth in severe alopecia cases after 24 weeks of daily oral dosing in large trials.

Upadacitinib, a drug developed for arthritis, demonstrated hair regrowth in two Phase 3 clinical trials for severe alopecia areata. The studies enrolled 1,399 participants aged 12–64 years, including 118 adolescents, all with ≥50% scalp hair loss (SALT score ≥50). After 24 weeks, 55% of patients on 30 mg daily dosing achieved at least 80% scalp hair coverage (SALT score ≤20), while 45.2% on 15 mg dosing reached this threshold. Full scalp hair regrowth occurred in 13–22.5% of participants on upadacitinib versus 1.5–3.4% on placebo. The drug was administered orally at 15 mg or 30 mg doses, with trials published in JAMA Dermatology (2026). This non-surgical treatment offers a potential pathway to address severe hair loss, reducing mental health burdens for patients who previously had limited options.

The mechanism involves the drug’s established anti-inflammatory action repurposed for autoimmune hair loss. Its efficacy in this application is significant given the trial’s large scale and focus on severe cases where conventional treatments often fail. For individuals with severe alopecia, this represents a new option that could improve quality of life without surgery.

This advancement moves abundance for mental health and self-esteem needs in severe hair loss cases. It provides a scalable, non-invasive solution that could reduce reliance on costly hair transplants or psychological support. However, long-term effects remain unknown after only 24 weeks of treatment, and further testing against existing alopecia therapies is needed to confirm real-world impact. The industry sponsorship by AbbVie and researcher affiliations with the company require transparent oversight as this technology progresses.

Source: ScienceAlert